InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Company Overview - InspireMD, Inc. is focused on developing the CGuard™ Embolic Prevention Stent System (EPS) aimed at preventing strokes [1][3] - The company utilizes proprietary MicroNet® technology to establish its products as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [3] Leadership Appointment - Scott R. Ward has been appointed to the Board of Directors, bringing extensive experience in the medical technology sector, particularly in cardiovascular health [1][2] - Ward previously served as CEO and President of Cardiovascular Systems, Inc. before its acquisition by Abbott in April 2023 [1][2] - His addition is expected to provide valuable insights as the company approaches potential U.S. approval of CGuard Prime, which is seen as a significant value inflection point for InspireMD [2] Strategic Goals - The company aims to advance its carotid platform and innovate its pipeline, including CAS, TCAR, and Neuro focuses, under Ward's guidance [2] - Ward believes that upon U.S. approval, CGuard will become a new standard of care for carotid intervention and stroke prevention, highlighting the strong data supporting its efficacy [2]